CIT-Logo-White Created with Sketch.
News Issue Archive Device Guide Calendar Subscribe Advertising

MENU

Device Guides
Trial Guide
Centers

Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions

News Current Issue Archive Device Guide Calendar Subscribe Advertising About Contact Privacy Submissions
Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions

Advertisement

Advertisement

Search Results

Show Filters

close Created with Sketch.

Refine by Content Type

close Created with Sketch.

Refine by Year

close Created with Sketch.

Advertisement

Sort By:

Relevance Date

Choose Sites to Search:

CIToday CIToday + EVToday

cit | Article | March/April 2021

An Interview With Rasha Al-Lamee, MA, MBBS, FRCP, PhD

Dr. Al-Lamee discusses the importance of research in cardiology care, thoughts on the ORBITA and EXCEL trials, and the effect of COVID-19 on the clinical trial landscape.

cit | Article | January/February 2022

Contemporary PCI and Structural Heart

By Rasha Al-Lamee, MD, and Rahul Sharma, MD

cit | Article | January/February 2020

Making Sense of ORBITA and ISCHEMIA

Discussing the contributions of the ORBITA and ISCHEMIA trials to the ongoing debate surrounding revascularization in stable coronary artery disease.

By Michael Foley, MBBS, MRCP, and Rasha Al-Lamee, MRCP, PhD

cit | Article | September/October 2023

Curbside Consult: The Biggest Clinical Trial Innovation Needs in…

Physicians consider priorities for future clinical trials in their respective interventional cardiology areas of focus, with responses spanning from a need for data informing treatment benefit and decision-making for current and future therapies to broader changes needed in the approach to research.

With Mirvat Alasnag, MD, FACC, FACP, FSCAI, FRCP; Salvatore Brugaletta, MD, PhD; Jay Giri, MD, MPH, FACC, FAHA, FSCAI; Rasha Al-Lamee, MA, MBBS, FRCP, PhD; Rishi Puri, MD, PhD, FRACP; and Gagan D. Singh, MD

Advertisement

Advertisement

cit | News | May 22, 2018

Physiology-Stratified Analysis of ORBITA Presented at EuroPCR

May 23, 2018—Results from the physiology-stratified analysis of ORBITA were presented at EuroPCR 2018, held May 21–25 in Paris, France by Rasha Al-Lamee, MD, Interventional Cardiology Consultant and Principal Investigator for ORBITA.

cit | News | March 9, 2018

Health Economic Data Presented From DEFINE-FLAIR Study of iFR-Guided Revascularization Strategy

March 10, 2018—Royal Philips announced health economic results comparing cost-effectiveness between instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) in the guidance of treating ischemic heart disease in the DEFINE-FLAIR clinical trial.

cit | Article | January/February 2020

PCI in Practice and Update on Mechanical Circulatory Support

By Christopher Cook, BSc, MBBS, MRCP, PhD, and M. Chadi Alraies, MD

cit | News | April 8, 2024

ORBITA-COSMIC Evaluates Coronary Sinus Reducer to Treat Refractory Angina

April 8, 2024—The placebo-controlled ORBITA-COSMIC study met one of its primary endpoints by showing symptom improvement with a coronary sinus reducer (CSR) at 6 months; however, it did not meet the main primary endpoint, which was designed to determine the mechanism by which the CSR might work.

cit | Article | September/October 2023

Modern Clinical Trials Spotlight

By Ori Ben-Yehuda, MD

cit | News | November 11, 2023

ORBITA-2 Shows PCI Relieves Chest Pain and Improves Exercise Capacity

November 11, 2023—The American Heart Association (AHA) announced that findings from the ORBITA-2 trial provide the first robust data confirming that percutaneous coronary intervention (PCI) relieves stable chest pain and improves exercise capacity among patients taking little or no chest pain medication.

cit | News | May 17, 2024

CathWorks Gains EU MDR Approval for FFRangio System

May 17, 2024—CathWorks announced that the company’s FFRangio system is now approved under the European Union (EU) Medical Device Regulation (MDR) 2017/745.

cit | Article | March/April 2021

Contemporary Issues in TAVR

By James McCabe, MD, and Darren Mylotte, MD

cit | News | September 28, 2021

Neovasc’s Reducer Device for Refractory Angina Evaluated in Interim Data From REDUCER-I Study

September 28, 2021—Neovasc Inc. announced the publication of interim results from the multicenter, prospective, open-label REDUCER-I clinical study investigating patients with refractory angina treated with the Neovasc Reducer system.

cit | News | November 1, 2017

Effect of PCI on Exercise Time Studied in Patients With Stable Angina and Single-Vessel Disease

November 2, 2017—Results from the ORBITA trial were reported at TCT 2017, the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium held October 30 to November 2 in Denver, Colorado, and were published simultaneously in The Lancet.


1

Advertisement

Advertisement

Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions
Centers

Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions

News• Current Issue• Archive• Device Guides• Advertising• About Calendar• Contact• Privacy• Submissions• Subscriptions


Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions.



magazine Created with Sketch.

Free Print Subscriptions

Fill 1 Created with Sketch.

Email Newsletter



twitter-icon LinkedIn Created with Sketch. BlueSky-Circle
Endovascular Today
CIT-Logo-Color Created with Sketch.
bmc-secondary-mark-color copy Created with Sketch.

© 2026 Bryn Mawr Communications II, LLC.  
All Rights Reserved   •   Privacy Policy

one-trust-button